

Law Offices
FOLEY & LARDNER
3600 K Street, NW, Suite 500
Washington, DC 20007-5109
(202) 672-5300

Atty. Dkt. No. 51916/107

jc713
01/24/00
U.S. PTO

Assistant Commissioner for Patents
BOX PATENT APPLICATIONS
Washington, DC 20231

jc511 U.S. PTO
09/489850
01/24/00

UTILITY PATENT APPLICATION TRANSMITTAL

[new nonprovisional applications under 37 C.F.R. §1.53(b)]

Transmitted herewith for filing is the patent application of:

INVENTOR(S): Diane VAN ALSTYNE, Lawrence Rajendra SHARMA

TITLE: PEPTIDES REPRESENTING EPITOPIC SITES FOR BACTERIAL AND VIRAL MENINGITIS CAUSING AGENTS AND THEIR CNS CARRIER, ANTIBODIES THERETO, AND USES THEREOF

In connection with this application, the following are enclosed:

APPLICATION ELEMENTS:

XX Specification - 86 TOTAL PAGES

(preferred arrangement:)

- Descriptive Title of the Invention
- Cross Reference to Related Applications
- Statement Regard Fed sponsored R&D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

XX Drawings - Total Sheets 12

XX Declaration and Power of Attorney - Total Sheets 2

____ Newly executed (original or copy)

XX Copy from a prior application (37 CFR 1.63(d))

(relates to continuation/divisional boxes completed) - NOTE: Box below

____ DELETION OF INVENTOR(S) - Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

XX Incorporation By Reference (useable if copy of prior application Declaration being submitted)

The entire disclosure of the prior application, from which a COPY of the oath or declaration is supplied as noted above, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

____ Microfiche Computer Program (Appendix)

XX Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)

X Submission of Sequence Listing under 37 C.F.R. §1.821(e)

X Paper Copy (identical to computer copy)

X Statement verifying identify of above copies

ACCOMPANYING APPLICATION PARTS

- ____ Assignment Papers (cover sheet & document(s))
- ____ 37 CFR 3.73(b) Statement (when there is an assignee)
- ____ English Translation Document (if applicable)
- ____ Information Disclosure Statement(IDS) with PTO-1449
- X Preliminary Amendments
- X Return Receipt Postcard (MPEP 503)
- X Small Entity Statement(s)

- Statement filed in prior application, status still proper and desired.
 Certified Copy of Priority Document(s) with Claim of Priority
(if foreign priority is claimed).
 OTHER:

If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

Continuation Divisional Continuation-in-part (CIP)
of prior Application Serial No. 08/988,444, which in turn is a
continuation of Application Serial No. 08/486,050, which in turn is a
continuation-in-part of Application Serial No. 08/127,499.

Amend the specification by inserting before the first line the following sentence: --This application is a continuation, divisional or continuation-in-part of Application Serial No. 08/988,444, filed December 11, 1997, which is a continuation of Application Serial No. 08/486,050, filed June 7, 1995, which is a continuation-in-part of Application Serial No. 08/127,499, filed September 28, 1993.--

CORRESPONDENCE ADDRESS:

Dr. Diane van Alstyne
INSIGHT BIOTEK INC.
130 MacPherson Avenue, No. 23, Toronto, Ontario M5R 1W8
(416) 961-4188 (telephone), (416) 923-5701 (telecopier)

FEE CALCULATIONS (small-entity fees indicated in parentheses):

(1) For	(2) Number Filed	(3) Number Extra	(4) Rate	(5) Basic Fee \$690 (\$345)
Total Claims	12 - 20 =	0	x \$18 (x \$ 9)	0
Independent Claims	2 - 3 =	0	x \$78 (x \$39)	0
Multiple Dependent Claims			\$260 (\$130)	0
Assignment Recording Fee per property			\$40	0
Surcharge Under 37 C.F.R. 1.16(e)			\$130 (\$65)	0
			TOTAL FEE:	\$345.00

METHOD OF PAYMENT:

A check in the amount of the above TOTAL FEE is attached. If payment by check is NOT enclosed, it is requested that the Patent and Trademark Office advise the undersigned of the period of time within which to file the TOTAL FEE. If payment enclosed, this amount is believed to be correct; however, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 19-0741.

Respectfully submitted,


Stephen A. Bent
Reg. No. 29,768

01/24/00
JG713 U.S. PTO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 051916/0107

10511 U.S. PTO
09/489850

A
01/24/00

In re patent application of
Diane VAN ALSTYNE et al.

Group Art Unit: Unassigned
Examiner: Unassigned

Serial No.: NEW

Filed: January 24, 2000

For: PEPTIDES REPRESENTING EPITOPIIC SITES FOR BACTERIAL
AND VIRAL MENINGITIS CAUSING AGENTS AND THEIR CNS
CARRIER, ANDIBODIES THERETO, AND USES THEREOF

LETTER

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

By virtue of a petition filed January 21, 1999, and granted August 30, 1999, the undersigned has withdrawn as attorney of record in connection with the present application and its parent, Serial No. 08/988,444, and is filing the present Rule 53(b) continuation application as a courtesy to a foreign national. Please forward all correspondence to: Dr. Diane van Alstyne, INSIGHT BIOTEK INC., 130 MacPherson Avenue, No. 23, Toronto, Ontario M5R 1W8.

Respectfully submitted,



Stephen A. Bent

Registration No. 29,768

January 24, 2000

Date

FOLEY & LARDNER
3000 K Street, NW, Suite 500
Washington, DC 20007-5109
(202) 672-5300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: 51916/107/INBI

JC511 U.S. PRO
09/489850
01/24/00

In re patent application of

Diane VAN ALSTYNE

Serial No. Unassigned

Group Art Unit: Unassigned

Filed: December 11, 1997

Examiner: Unassigned

For: PEPTIDES REPRESENTING EPITOPIIC SITES FOR BACTERIAL AND VIRAL MENINGITIS CAUSING AGENTS AND THEIR CNS CARRIER, ANTIBODIES THERETO, AND USES THEREOF

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents
Washington, D.C. 20231
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter; and

2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

Respectfully submitted,



Stephen A. Bent
Reg. No. 29,768

12-11-97
Date

FOLEY & LARDNER
Suite 500
3000 K Street, N.W.
Washington, D.C. 20007-5109
(202) 672-5300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No: 089048/01410

jc511 U.S. PTO
09/489850
01/24/00


In re patent application of

Diane VAN ALSTINE et al.

Box SEQUENCE

Serial No.: Unassigned

Group Art Unit: Unassigned

Filed: January 24, 2000

Examiner: Unassigned

For: PEPTIDES REPRESENTING EPITOPIC SITES FOR BACTERIAL AND VIRAL MENINGITIS CAUSING AGENTS AND THEIR CNS CARRIER, ANTIBODIES THERETO, AND USES THEREOF

SUBMISSION OF SEQUENCE LISTING UNDER 37 C.F.R. §1.821(e)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In order to comply with the requirements for patent applications containing amino acid and/or sequence disclosures, applicants refer to the Sequence Listing and the computer readable form thereof filed on December 11, 1997, in Parent Application Serial No. 08/988,444, which contains sequence information identical to that of the present application. Applicants hereby request, therefore, that the Sequence Listing of the parent application be used to fulfill the sequence disclosure requirements for the application in caption pursuant to 37 C.F.R. § 1.821(e). Enclosed are copies of the Sequence Listing and Statement to Support Filing and Submission in accordance with 37 C.F.R. §§ 1.821-1.825, which were filed in the parent application. Also enclosed is a copy of the Preliminary Amendments filed December 11, 1997, and March 31, 1999, which, among other changes, inserted the required references to SEQ ID NOS and requested incorporation of the Sequence Listing into the specification.

Applicants respectfully request examination of the instant application on the merits in due course.

Respectfully submitted,



Stephen A. Bent
Reg. No. 29,768

24 January 2000

Date

FOLEY & LARDNER
3000 K Street, NW, Suite 500
Washington, DC 20007
(202) 672-5300